Latest Biome Australia (ASX:BIO) News

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

Biome Australia has partnered with Fullscript to distribute its Activated Probiotics range across Canada, complementing its existing wholesale network and marking a key step in its international growth.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Biome Australia Limited has reported a record quarterly revenue of $5.94 million for Q1 FY26, marking a 40% increase year-over-year and its seventh consecutive quarter of positive EBITDA. The company’s strong cash flow and sustained margins underscore its growth momentum.

Biome Australia Limited has reported a record-breaking $5.94 million in sales revenue for Q1 FY26, surpassing forecasts and accelerating toward its ambitious Vision 27 revenue goals.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

Biome Australia has partnered with Green Cross Health to launch its Activated Probiotics across New Zealand’s largest pharmacy network, marking a pivotal step in its international growth strategy.

Biome Australia has secured key distribution partnerships with Mecca and Go Vita, launching its Activated Probiotics range into premium beauty and health food channels across Australia.